A Field Study to Observe Symptom Scores and Allergy Medication Usage in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis
Phase of Trial: Phase IV
Latest Information Update: 29 Apr 2015
Price : $35 *
At a glance
- Drugs HDM SPIRE (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Circassia
- 14 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Feb 2014 to 1 Mar 2014.
- 20 Feb 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.